Biotech GSK's cell therapy R&D lead jumps ship to partner Immatics

Just a few months after GlaxoSmithKline penned a $50 million deal with biotech Immatics for its T-cell work, the executive running the Big Pharma’s cancer cell therapy unit is upping sticks to join the U.S.-European startup.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and T-cell receptor (TCR) bispecifics platform, which is focused on various solid tumors.